MedPath
Found 50 clinical trials|View Analysis
Sort by:

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Phase 4
Not yet recruiting
Conditions
Biliary Malignant Tumors
Interventions
First Posted Date
2024-11-12
Last Posted Date
2024-11-20
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
70
Registration Number
NCT06685289

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma with PVTT
Interventions
Procedure: Transjugular intrahepatic portosystemic shunt (TIPS)
Drug: Donafenib
First Posted Date
2024-10-17
Last Posted Date
2024-10-17
Lead Sponsor
Fei Gao
Target Recruit Count
40
Registration Number
NCT06646198
Locations
🇨🇳

Sun Yat-sen University, Guangzhou, Guangdong, China

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Not Applicable
Recruiting
Conditions
Hepatocellular Carcinoma
Microwave Ablation
Donafenib
Recurrent Tumor
Interventions
Procedure: Thermal ablation
Drug: Donafenib
First Posted Date
2024-09-24
Last Posted Date
2024-12-03
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
108
Registration Number
NCT06609876
Locations
🇨🇳

Chinese PLA General hospital, Beijing, None Selected, China

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Not Applicable
Recruiting
Conditions
Hepatocellular Carcinoma
Adjuvant Therapy
Interventions
First Posted Date
2024-09-03
Last Posted Date
2024-09-03
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
204
Registration Number
NCT06581315
Locations
🇨🇳

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Phase 2
Not yet recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2024-07-22
Last Posted Date
2024-07-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT06512467

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2024-07-12
Last Posted Date
2024-07-12
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
45
Registration Number
NCT06498622
Locations
🇨🇳

No.2 People's Hospital of Fuyang city, Fuyang, Anhui, China

🇨🇳

Anhui province hospital, Hefei, Anhui, China

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

Phase 4
Not yet recruiting
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Drug: Donafenib
Procedure: transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy
Drug: PD-1,PD-L1
First Posted Date
2024-07-11
Last Posted Date
2024-07-11
Lead Sponsor
Tongji Hospital
Target Recruit Count
32
Registration Number
NCT06496815

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

First Posted Date
2024-07-01
Last Posted Date
2024-12-05
Lead Sponsor
West China Hospital
Target Recruit Count
75
Registration Number
NCT06482086
Locations
🇨🇳

West China hospital, Chengdu, Sichuan, China

HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Donafenibï¼› Sintilimabï¼› HAIC
First Posted Date
2024-02-06
Last Posted Date
2024-02-06
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
38
Registration Number
NCT06244225
Locations
🇨🇳

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
Drug: ZG005 Powder for Injection
Drug: Donafenib Tosilate Tablets
First Posted Date
2024-02-02
Last Posted Date
2024-06-14
Lead Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Target Recruit Count
130
Registration Number
NCT06239298
Locations
🇨🇳

The Second Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath